Xiangxue PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Xiangxue PharmaceuticalLtd's earnings have been declining at an average annual rate of -52.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 5.6% per year.
Key information
-52.4%
Earnings growth rate
-52.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -5.6% |
| Return on equity | -19.2% |
| Net Margin | -18.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Xiangxue PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,279 | -429 | 581 | 89 |
| 31 Dec 23 | 2,299 | -389 | 583 | 90 |
| 30 Sep 23 | 2,170 | -381 | 578 | 76 |
| 30 Jun 23 | 2,197 | -429 | 600 | 83 |
| 31 Mar 23 | 2,162 | -474 | 623 | 99 |
| 31 Dec 22 | 2,187 | -533 | 624 | 95 |
| 30 Sep 22 | 2,480 | -1,004 | 744 | 105 |
| 30 Jun 22 | 2,626 | -909 | 675 | 109 |
| 31 Mar 22 | 2,793 | -767 | 662 | 92 |
| 01 Jan 22 | 2,971 | -688 | 660 | 91 |
| 30 Sep 21 | 2,814 | -33 | 599 | 82 |
| 30 Jun 21 | 2,791 | 8 | 599 | 68 |
| 31 Mar 21 | 3,065 | 42 | 591 | 69 |
| 31 Dec 20 | 3,072 | 98 | 590 | 67 |
| 30 Sep 20 | 3,297 | 132 | 577 | 59 |
| 30 Jun 20 | 3,278 | 162 | 608 | 63 |
| 31 Mar 20 | 2,931 | 126 | 619 | 63 |
| 31 Dec 19 | 2,786 | 77 | 621 | 61 |
| 30 Sep 19 | 2,644 | 57 | 629 | 56 |
| 30 Jun 19 | 2,596 | 59 | 592 | 42 |
| 31 Mar 19 | 2,571 | 61 | 602 | 41 |
| 31 Dec 18 | 2,504 | 56 | 604 | 39 |
| 30 Sep 18 | 2,400 | 87 | 625 | 34 |
| 30 Jun 18 | 2,303 | 71 | 624 | 56 |
| 31 Mar 18 | 2,292 | 69 | 578 | 45 |
| 31 Dec 17 | 2,187 | 66 | 530 | 40 |
| 30 Sep 17 | 2,167 | 60 | 477 | 25 |
| 30 Jun 17 | 2,165 | 61 | 489 | 0 |
| 31 Mar 17 | 2,013 | 57 | 475 | 0 |
| 31 Dec 16 | 1,862 | 66 | 452 | 0 |
| 30 Sep 16 | 1,700 | 109 | 429 | 0 |
| 30 Jun 16 | 1,527 | 137 | 412 | 0 |
| 31 Mar 16 | 1,418 | 170 | 380 | 0 |
| 31 Dec 15 | 1,465 | 177 | 386 | 0 |
| 30 Sep 15 | 1,470 | 190 | 372 | 0 |
| 30 Jun 15 | 1,530 | 200 | 364 | 0 |
| 31 Mar 15 | 1,546 | 200 | 367 | 0 |
| 31 Dec 14 | 1,524 | 197 | 356 | 0 |
| 30 Sep 14 | 1,602 | 203 | 327 | 0 |
| 30 Jun 14 | 1,554 | 193 | 312 | 0 |
| 31 Mar 14 | 1,408 | 173 | 288 | 0 |
| 31 Dec 13 | 1,261 | 158 | 266 | 0 |
| 30 Sep 13 | 1,047 | 134 | 259 | 0 |
| 30 Jun 13 | 911 | 120 | 240 | 0 |
Quality Earnings: 300147 is currently unprofitable.
Growing Profit Margin: 300147 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300147 is unprofitable, and losses have increased over the past 5 years at a rate of 52.4% per year.
Accelerating Growth: Unable to compare 300147's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300147 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.6%).
Return on Equity
High ROE: 300147 has a negative Return on Equity (-19.2%), as it is currently unprofitable.